Trial Profile
Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel Design Study to Evaluate the Efficacy and Safety of Intravenous Tedisamil Sesquifumarate in the Rapid Conversion to Normal Sinus Rhythm in Male Subjects With Recent Onset Atrial Fibrillation or Flutter
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 19 Jan 2015
Price :
$35
*
At a glance
- Drugs Tedisamil (Primary)
- Indications Atrial fibrillation; Atrial flutter
- Focus Registrational; Therapeutic Use
- Sponsors Solvay Pharmaceuticals
- 20 Apr 2010 Additional trial locations identified as reported by ClinicalTrials.gov.
- 29 Oct 2005 New trial record.